Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638722 | 0.86 | CRHR1 (0.48) | CRHR1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2638716 | 0.80 | CRHR1 (0.52) | CRHR1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1849317 | 0.70 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL13493665 | 0.68 | GRIN2B (0.46) | NPC1RAB9ASMN1; SMN2HPGDHTT | |
| SCHEMBL2586747 | 0.66 | ALDH1A1 (0.53) | RAB9ASMN1; SMN2ALDH1A1GAACYP2C9 | |
| SCHEMBL1747209 | 0.66 | ALDH1A1 (0.43) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2581646 | 0.65 | ALDH1A1 (0.52) | RAB9AALDH1A1GAAMAPTACHE | |
| SCHEMBL18483306 | 0.65 | ALDH1A1 (0.42) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL13493711 | 0.65 | KDM1A (0.38) | CRHR1SMN1; SMN2HPGDMAPK1HSD17B10 | |
| SCHEMBL13026587 | 0.65 | RAB9A (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273900-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20110152261-A1 | Organic compounds | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20100035898-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035898-A1 | Organic compounds | CRH, CRHR1, CRHR2 | CRHR1 2/4885NPC1 784/4885RAB9A 3533/4885 |
| US-20110152261-A1 | Organic compounds | CRH, CRHR1, CRHR2 | CRHR1 2/4885NPC1 627/4885RAB9A 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.